foxo4 dri senolytic human trial 2024 2025 FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation FOXO4-DRI: The Senolytic Peptide That

and around the world

It achieves this by enhancing blood flow through angiogenesis, the formation of new blood vessels, which is essential for supplying nutrients and oxygen to injured areas and removing waste and inflammatory byproducts[2][5]

As of June 2026 there are no completed or registered human clinical trials for FOXO4-DRI

BPC-157 resists enzymatic breakdown which is precisely why oral delivery is a meaningful research variable for this compound, not a theoretical one.2 But that stability does not mean every delivery route produces the same result

Tissue healing takes weeks

Patients encountering online sources or private clinics offering this combination should exercise significant caution, as: Unregulated supply of investigational peptides carries serious safety risks Quality, purity, and dosing of unlicensed products cannot be guaranteed Use outside of a clinical trial setting is not supported by current evidence or regulatory frameworks For those seeking access to obesity treatments within a safe and monitored environment, NICE-approved pathways for existing licensed therapies remain the appropriate starting point